Covered by Medicare.

Prolaris® Prostate Cancer Genomic Assay

  • L36350: LCD for NCCN very low- and low-risk
  • L37082: LCD for NCCN favorable intermediate-risk

Register to Download PDFs

Prognostic information independent of NCCN risk groups.

“Men with clinically localized disease may consider the use of tumor-based molecular assays. Retrospective case cohort studies have shown that molecular assays performed on biopsy or prostatectomy specimens provide prognostic information independent of NCCN risk groups.

[Men with] favorable intermediate-risk prostate cancer (predominant Gleason grade 3 [i.e., Gleason score 3+4=7], and percentage of positive biopsy cores <50 percent, and no more than one NCCN intermediate risk factor) can be considered for active surveillance.”

National Comprehensive Cancer Network® NCCN Clinical Guidelines in Oncology (NCCN Guidelines®) Prostate Cancer Version 1.2018. Available at www.nccn.org.

Register to Download PDF